



VOLUME ONE HUNDRED AND FOURTEEN

ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY

Molecular Chaperones in Human Disorders

Edited by

ROSSEN DONEV

*MicroPharm Ltd,
United Kingdom*



*Mahidol University
Faculty of Science*

Song Mangkolak Library and Information Unit on



ACADEMIC PRESS

An imprint of Elsevier

Contents

<i>Contributors</i>	<i>xi</i>
<i>Preface</i>	<i>xv</i>
1. Functional principles and regulation of molecular chaperones	1
Vinay Dahiya and Johannes Buchner	
1. Protein folding	2
2. The concept of molecular chaperones	3
References	41
2. Protein stability and degradation in health and disease	61
Lene Clausen, Amanda B. Abildgaard, Sarah K. Gersing, Amelie Stein, Kresten Lindorff-Larsen, and Rasmus Hartmann-Petersen	
1. Introduction	62
2. Protein quality control	63
3. The UPS in protein quality control	64
4. Protein quality control in cellular compartments	66
5. Degradation signals	68
6. The consequence of missense mutations for protein stability	70
7. The role of chaperones in protein evolution and manifestation of genetic disorders	73
8. The protein quality control pathway as a drug target for protein conformational diseases	75
9. Concluding remarks	76
Competing interests	77
Funding	77
References	77
3. Chaperones and retinal disorders	85
Maxim Sokolov, Ravi P. Yadav, Celine Brooks, and Nikolai O. Artemyev	
1. Introduction	86
2. Folding and assembly of transducin $\beta\gamma$: The role of chaperonin	88
3. CCT and the assembly of the BBSome	92
4. Does transducin α require a chaperone?	93
5. AIPL1 is a specialized chaperone of PDE6	96

6. UNC119 and PDE6D as trafficking chaperones of transducin and PDE6	100
7. Outlook	106
Acknowledgment	106
References	106
4. Structural and functional insights on the roles of molecular chaperones in the mistargeting and aggregation phenotypes associated with primary hyperoxaluria type I	119
José Ángel Fernández-Higuero, Isabel Betancor-Fernández, Noel Mesa-Torres, Arturo Muga, Eduardo Salido, and Angel L. Pey	
1. Molecular chaperones in protein homeostasis	120
2. Primary hyperoxaluria type I (PH1): A LOF disease associated with peroxisomal aggregation and mitochondrial mistargeting	131
3. Small molecule correction of protein homeostasis defects in PH1: Pyridoxine responsiveness and modulators of protein homeostasis and mitochondrial import	140
4. Outlook and future directions	141
Acknowledgments	143
References	143
5. Inflammatory response and its relation to sphingolipid metabolism proteins: Chaperones as potential indirect anti-inflammatory agents	153
Z. Begum Yagci, Elif Esvap, Hatice Asuman Ozkara, Kutlu O. Ulgen, and Elif Ozkirimli Olmez	
1. Introduction	155
2. Inflammation	159
3. Sphingolipid metabolism	163
4. Sphingolipids involved in inflammation	166
5. Protein-protein interaction network for the crosstalk between inflammation and sphingolipid metabolism	173
6. Neuroinflammation, inflammatory diseases and sphingolipids	177
7. Inherited disorders of lysosomal sphingolipid metabolism: Sphingolipidoses	181
8. Sphingolipidoses and inflammation	187
9. Conclusions and future perspectives	197
Acknowledgments	201
References	201

6. When safeguarding goes wrong: Impact of oxidative stress on protein homeostasis in health and neurodegenerative disorders	221
Ravit Mesika and Dana Reichmann	
1. Introduction	222
2. Cellular oxidants: Origin, targets, and benefits	223
3. How do cells overcome oxidative stress and protect their proteome?	227
4. Global transcription factors mediate the oxidative stress response	236
5. The crosstalk between proteostasis and redox homeostasis in age-associated neurodegenerative disorders (NDs)	238
6. Modulating protein homeostasis to treat neurodegenerative diseases	250
References	251
7. The roles of cytosolic quality control proteins, SGTA and the BAG6 complex, in disease	265
Rashi Benarroch, Jennifer M. Austin, Fahmeda Ahmed, and Rivka L. Isaacson	
1. Introduction	266
2. Hydrophobic parts of proteins exposed to the cytoplasm pose an aggregation risk	267
3. The specific case of tail-anchored proteins	268
4. Triage and fate of hydrophobic substrates in the cytoplasm	268
5. SGTA	270
6. SGTA structure	270
7. Regulation of cytosolic quality control by SGTA	272
8. Role of SGTA in neurodegenerative diseases	273
9. The androgen signaling pathway and SGTA	274
10. The role of SGTA in prostate cancer	274
11. The role of SGTA in polycystic ovary syndrome	275
12. The role of SGTA in breast cancer	276
13. SGTA in the cell cycle	276
14. The role of SGTA in lung cancer	277
15. The role of SGTA in esophageal cancer	277
16. Early identifications of SGTA in viral infections	278
17. SGTA and the simian virus 40	278
18. BAG6	279
19. BAG6 structure	280
20. BAG6 structure: N-Terminal UBL domain	281
21. BAG6 structure: C-Terminal BAG domain	282
22. BAG6 structure: NLS domain	283

23. BAG6 is an essential apoptotic regulator of nascent polypeptides	284
24. BAG6 involved in the triage system during protein quality control	285
25. BAG6 coupled degradation of defective nascent polypeptides	285
26. BAG6 complex—Structural interaction with UBL4A	288
27. BAG6 associations with disease	289
28. The role of BAG6 in male infertility	289
29. The role of BAG6 in lung cancer	290
30. The role of BAG6 in osteoarthritis	290
31. The role of BAG6 in autoimmune disease	291
32. BAG6: future prospects	292
33. Other members of the BAG6 complex and machinery for TA protein insertion	292
34. Formation of the Get4/5 and cBag6 complex	294
35. Structures and binding domains of proteins in the Get4/5 and the cBag6 complexes	295
36. Protein-protein interactions of the Get4/5 (cBag6) complex in the GET/TRC pathway	297
37. Interaction of Get4/5 (cBag6) complex with Sgt2 (SGTA)	297
38. Interaction of Get4/5 (cBag6) complex with Get3 (TRC40)	299
39. Protein interactions in the TRC(GET) pathway	301
40. Disease related to this quality control system	302
41. Disease seemingly unrelated to the chaperone system	304
42. Conclusion	305
References	305
8. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease	315
D. Thirumal Kumar, Sharada Iyer, J. Priyadharshini Christy, R. Siva, Iftikhar Aslam Tayubi, C. George Priya Doss, and Hatem Zayed	
1. Introduction	316
2. Materials and methods	318
3. Results	320
4. Discussion	332
5. Conclusion	335
Acknowledgments	335
Disclosure statement	335
References	335
Further reading	339

9. Computational and modeling approaches to understand the impact of the Fabry's disease causing mutation (D92Y) on the interaction with pharmacological chaperone 1-deoxygalactonojirimycin (DGJ)	341
D. Thirumal Kumar, E. Judith, J. Priyadharshini Christy, R. Siva, Iftikhar Aslam Tayubi, Chiranjib Chakraborty, C. George Priya Doss, and Hatem Zayed	
1. Introduction	342
2. Methods and materials	344
3. Results	346
4. Discussion	401
5. Conclusion	404
Acknowledgments	404
Disclosure statement	404
References	405